A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

This study describes a double-blind randomized placebo-controlled phase I clinical trial in healthy adults of a new potential pandemic H7N9 live attenuated influenza vaccine (LAIV) based on the human influenza virus of Yangtze River Delta hemagglutinin lineage (ClinicalTrials.gov Identifier: NCT0373...

Full description

Bibliographic Details
Main Authors: Irina Kiseleva, Irina Isakova-Sivak, Marina Stukova, Marianna Erofeeva, Svetlana Donina, Natalie Larionova, Elena Krutikova, Ekaterina Bazhenova, Ekaterina Stepanova, Kirill Vasilyev, Victoria Matyushenko, Marina Krylova, Julia Galatonova, Aleksey Ershov, Dmitry Lioznov, Erin Grace Sparrow, Guido Torelli, Larisa Rudenko
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Vaccines
Subjects:
H7N9 influenza
potential pandemic vaccine
LAIV
clinical trial
safety
stability
Online Access:https://www.mdpi.com/2076-393X/8/2/296

Internet

https://www.mdpi.com/2076-393X/8/2/296

Similar Items